Skip to main content

Advertisement

SpringerLink
Log in

Kawasaki disease: An update

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Kawasaki disease (KD) was first reported in Japan more than 30 years ago, but the original diagnostic clinical criteria defined by Dr. Kawasaki are still authentic. The cause of KD remains unknown. Several epidemiologic and clinical observations suggest that it is caused by one or multiple infectious agents, each of which can result in the clinical manifestation of the disease. Advances have been made in the management of the disease with the introduction of aspirin and intravenous immunoglobulin (IVIG) that have had a significant impact on lowering the rate of coronary artery aneurysms and death from the disease. Questions remain regarding the management of those patients whose disease does not respond to IVIG. Some patients with severe KD who are resistant to IVIG may benefit from IV pulse steroids therapy. It remains to be seen whether steroid or other anti-inflammatory agents play a role in the management of patients with KD. Further research studies are needed to identify the possible cause, define the treatment, and predict the long-term outcome of this enigmatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Dajani AS, Taubert KA, Gerber MA, et al.: Diagnosis and therapy of Kawasaki disease in children. Circulation 1993, 87:1776–1780.

    PubMed  CAS  Google Scholar 

  2. Kawasaki T: Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes. Jpn J Allergy 1967, 16:178–222.

    CAS  Google Scholar 

  3. No authors listed: Multiple outbreaks of Kawasaki syndrome —United States. MMWR Morb Mort Wkly Rep 1985, 34:33–35.

    Google Scholar 

  4. Yanagawa H, Nakamura Y, Ojima T, et al.: Changes in epidemic patterns of Kawasaki disease in Japan. Pediatr Infect Dis J 1999, 18:64–66. Presents data on the incidence of KD in Japan after the major outbreaks that occurred between 1979 and 1986. The paper suggests that nationwide epidemics have been replaced by local epidemics that developed at a different time.

    Article  PubMed  CAS  Google Scholar 

  5. Holman RC, Belay ED, Clarke MJ, et al.: Kawasaki syndrome among American Indian and Alaska native children. Pediatr Infect Dis J 1999, 18:451–455. Reports on KD in Native American children of Alaska.

    Article  PubMed  CAS  Google Scholar 

  6. Mason WH, Takahashi M: Kawasaki syndrome. Clin Infect Dis 1999, 28:169–185.

    PubMed  CAS  Google Scholar 

  7. Yanagawa H, Yashiro M, Nakamura Y, et al.: Nationwide surveillance of Kawasaki disease in Japan. Pediatr Infect Dis J 1995, 14:69–71.

    PubMed  CAS  Google Scholar 

  8. Cohen BJ: Human parvovirus B19 infection in Kawasaki disease [letter]. Lancet 1994, 344:59.

    Article  PubMed  CAS  Google Scholar 

  9. Marchette NJ, Melish ME, Hicks R, et al.: Epstein-Barr virus and other herpes infections in Kawasaki syndrome. J Infect Dis 1990, 161:680–684.

    PubMed  CAS  Google Scholar 

  10. Whitby D, Hoad JG, Tizard TJ, et al.: Isolation of measles virus from a child with Kawasaki disease. Lancet 1991, 338:1215.

    Article  PubMed  CAS  Google Scholar 

  11. Dajani AS, Taubert KA, Gerber MA, et al.: Diagnosis and therapy of Kawasaki disease in children. Circulation 1993, 87:1776–1780.

    PubMed  CAS  Google Scholar 

  12. Abinum M, Cant AJ: Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome [letter]. Lancet 1994, 343:300.

    Article  Google Scholar 

  13. Davis HD, Kirk V, Jadavji T, et al.: Simultaneous presentation of Kawasaki disease and toxic syndrome in an adolescent male. Pediatr Infect Dis J 1996, 15:1136–1137.

    Article  Google Scholar 

  14. Meissner HC, Leung DYM: Superantigens, conventional antigens and etiology of Kawasaki syndrome. Pediatric Infect Dis J 2000, 19:91–94. The authors present the superantigens theory in the etiology of KD. They propose that in KD and TSS, the disease caused by viral or bacterial toxins that act as superantigens which bypass the usual, highly sophisticated antigen-specific presenting mechanism by binding to the Vβ region of the T-cell receptor.

    Article  CAS  Google Scholar 

  15. Leung DYM, Meissner HC, Fulton DR, et al.: Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993, 342:1385–1387.

    Article  PubMed  CAS  Google Scholar 

  16. Terai M, Miwa K, Williams T, et al.: The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J Infect Dis 1995, 172:558–561.

    PubMed  CAS  Google Scholar 

  17. Cassidy JT, Petty RE: Kawasaki disease. In Textbook of Pediatric Rheumatology, edn 3. Philadelphia: WB Saunders; 1995:372–383.

    Google Scholar 

  18. Kawasaki T, Kosaki T, Okawa S, et al.: A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974, 54:271–276.

    PubMed  CAS  Google Scholar 

  19. Morens D, O’Brien R: Kawasaki disease in the United States. J Infect Dis 1978, 137:91–93.

    PubMed  CAS  Google Scholar 

  20. Levy M, Koren G: Atypical Kawasaki disease: analysis of clinical presentation and diagnostic clues. Pediatr Infect Dis J 1990, 9:122–126.

    Article  PubMed  CAS  Google Scholar 

  21. Dajani AS, Taubert KA, Takahashi M, et al.: Guidelines for long-term management of patients with Kawasaki disease. Circulation 1994, 89:916–922.

    PubMed  CAS  Google Scholar 

  22. Newberger JW, Takahashi M, Beiser AS, et al.: A single intravenous infusion of gammaglobulin as compared with four infusions in treatment of acute Kawasaki syndrome. N Engl J Med 1991, 324:1633–1639.

    Article  Google Scholar 

  23. Durongpisitkul K, Gururaj VJ, Park JM, Martin CF: The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment. Pediatrics 1995, 96:1057–1061.

    PubMed  CAS  Google Scholar 

  24. Sundel RP, Burns JC, Baker A, Beiser A: Gamma globulin retreatment in Kawasaki disease. J Pediatr 1993, 123:657–659.

    Article  PubMed  CAS  Google Scholar 

  25. Melish ME: Kawasaki syndrome. Pediatr Rev 1996, 17:153–162.

    PubMed  CAS  Google Scholar 

  26. Wright DA, Newburger JW, Baker A, Sundel RP: Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996, 128:146–149.

    Article  PubMed  CAS  Google Scholar 

  27. Shetty AK, Homsi O, Ward K, Gedalia A: Massive lymphadenopathy and airway obstruction in a child with Kawasaki disease: success with pulse steroid therapy. J Rheumatol 1998, 25:1215–1217.

    PubMed  CAS  Google Scholar 

  28. Dahlem PG, Rosenstiel IA, Lam J, Kuijpers TW: Pulse methylprednisolone therapy for impending cardiac tamponade in immunoglobulin-resistant Kawasaki disease. Intensive Care Med 1999, 25:1137–1139.

    Article  PubMed  CAS  Google Scholar 

  29. Kato H, Koike S, Yokoyama T: Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979, 3:175–179.

    Google Scholar 

  30. Kijima Y, Kamiya T, Suzuki A, et al.: A trial procedure to prevent aneurysm formation of the coronary artery by steroid pulse therapy in Kawasaki disease. Jpn Circ J 1982, 46:1239–1242.

    PubMed  CAS  Google Scholar 

  31. Nonaka Z, Maekawa K, Okabe T, et al.: Randomized controlled study of intravenous prednisolone and gammaglobulin treatment in 100 cases with Kawasaki disease. In Kawasaki disease. Proceedings of the 5th International Kawasaki disease Symposium. Edited by Kato H. Amsterdam: Elsevier Science BV; 1995:328–331.

    Google Scholar 

  32. Shinohara M, Sone K, Tomomasa T, Morikawa A: Corticosteroids in the treatment of acute phase of Kawasaki disease. J Pediatr 1999, 135:465–469. In a retrospective study, the authors report on their 16 years of experience in the management of KD. Their data suggest that steroids may have a role in the treatment of the acute phase of KD. The authors also show that patients with KD who received 1 week of daily methylprednisolone, or a combination of methylprednisolone and IVIG, developed less CAA compared with those who did not.

    Article  PubMed  CAS  Google Scholar 

  33. Newburger JW: Treatment of Kawasaki disease: corticosteroids revisited. J Pediatr 1999, 135:411–413. In this Editorial, the author discusses the possible role of steroids in the treatment of Kawasaki disease, while reviewing the most relevant medical literature. The author recommends that the efficacy of steroids administration in the treatment of KD should be reassessed with randomized, controlled trials. This may require a large sample size because the frequency of CAA is already < 5%.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Pediatrics, LSU Health Sciences Center and Children’s Hospital, 1542 Tulane Avenue, T8-1, 70112, New Orleans, LA, USA

    Abraham Gedalia MD

Authors
  1. Abraham Gedalia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gedalia, A. Kawasaki disease: An update. Curr Rheumatol Rep 4, 25–29 (2002). https://doi.org/10.1007/s11926-002-0020-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-002-0020-2

Keywords

Search

Navigation